Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Wallace, A, Darcy, K, Alvarez-Secord, A, Hutson, A, Tritchler, D, Kirchgraber, L, Grace, L, Whitaker, R, Berchuck, A, and Havrilesky, L. "Loss of p16 in advanced stage epithelial ovarian cancer is associated with chemoresistant disease, suboptimal debulking and poor progression-free survival: A Gynecologic Oncology Group study." GYNECOLOGIC ONCOLOGY 125 (March 2012): S37-S37.

Full Text

Berchuck, A, Secord, AA, and Havrilesky, LJ. "Minimally invasive surgery for endometrial cancer: the horse is already out of the barn." J Clin Oncol 30, no. 7 (March 1, 2012): 681-682.

Full Text

Rodriguez, GC, Turbov, JM, Berchuck, A, Stack, MS, Hurteau, JA, Thaete, LG, and Barry, CP. "Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells." Am J Obstet Gynecol 206, no. 3 (March 2012): 253.e1-253.e9.

Full Text

White, KL, Schildkraut, JM, Palmieri, RT, Iversen, ES, Berchuck, A, Vierkant, RA, Rider, DN, Charbonneau, B, Cicek, MS, Sutphen, R, Birrer, MJ, Pharoah, PPD, Song, H, Tyrer, J, Gayther, SA, Ramus, SJ, Wentzensen, N, Yang, HP, Garcia-Closas, M, Phelan, CM, Cunningham, JM, Fridley, BL, Sellers, TA, Goode, EL, and Ovarian Cancer Association Consortium, . "Ovarian cancer risk associated with inherited inflammation-related variants." Cancer Research 72, no. 5 (March 2012): 1064-1069.

Full Text

"Retraction. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 6 (February 2012): 678-null.

Full Text

Havrilesky, LJ, Pokrzywinski, R, Revicki, D, Higgins, RV, Nycum, LR, Kohler, MF, Berchuck, A, Myers, ER, and Secord, AA. "Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer." Cancer 118, no. 2 (January 15, 2012): 386-391.

Full Text

Allard, JE, Chandramouli, GVR, Stagliano, K, Hood, BL, Litzi, T, Shoji, Y, Boyd, J, Berchuck, A, Conrads, TP, Maxwell, GL, and Risinger, JI. "Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer. (Published online)" Front Oncol 2 (2012): 65-.

Full Text

Pearce, CL, and Berchuck, A. "Endometriosis and ovarian cancer - Authors' reply." The Lancet Oncology 13, no. 5 (2012): e190-.

Full Text

Lowery, WJ, Schildkraut, JM, Akushevich, L, Bentley, R, Marks, JR, Huntsman, D, and Berchuck, A. "Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers." Int J Gynecol Cancer 22, no. 1 (January 2012): 9-14.

Full Text

Kelemen, LE, Wang, Q, Dinu, I, Vierkant, RA, Tsai, Y-Y, Cunningham, JM, Phelan, CM, Fridley, BL, Amankwah, EK, Iversen, ES, Berchuck, A, Schildkraut, JM, Goode, EL, and Sellers, TA. "Regular Multivitamin Supplement Use, Single Nucleotide Polymorphisms in ATIC, SHMT2, and SLC46A1, and Risk of Ovarian Carcinoma." Frontiers in Genetics 3 (January 2012): 33-null.

Full Text

Pages